TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Thursday. The firm set a “hold” rating on the stock.

TherapeuticsMD Trading Down 6.4 %

Shares of TXMD stock opened at $1.47 on Thursday. TherapeuticsMD has a twelve month low of $0.70 and a twelve month high of $2.75. The stock has a 50 day moving average of $1.32 and a 200 day moving average of $1.58.

Institutional Trading of TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Clearline Capital LP increased its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.